Last Thursday, the first dose in Canada of a new biologic treatment for psoriasis was injected at Charlton Health. Guselkumab is marketed under the name of Tremfya and is approved by Health Canada for moderate to severe plaque psoriasis. It is given by injection using a pre-filled syringe on day 1 of treatment, followed by an injection on day 28 and a maintenance of every 8 weeks. Guselkumab works by removing an inflammatory cytokine called interleukin 23, which is produced in excess in the skin cells of patients with psoriasis. We are very excited to be offering this new and effective treatment at Charlton Health.
Pulmonary arterial hypertension occurs when there is increased pressure in the small blood vessels that…
Polymyalgia rheumatica (PMR) is an inflammatory condition that causes widespread joint and muscle pain along…
Respiratory Syncytial Virus (RSV) is a common virus that can cause serious lung infections, particularly in…
Health Canada has recently approved Rinvoq (upadacitinib) for adults living with Giant Cell Arteritis (GCA). Rinvoq…
Every year on October 12, World Arthritis Day raises awareness about the millions of people…
Tremfya (guselkumab) has been available for several years to treat plaque psoriasis and psoriatic arthritis.…